Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Weilong Yao"'
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/3f84011b7747475099ba792835fcb4fa
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 29, Iss , Pp 100798- (2022)
New treatment options, such as targeted therapies, are urgently needed for the treatment of colorectal cancer (CRC), the third leading cause of cancer-related deaths worldwide. The current study focuses on demonstrating the therapeutic efficacies of
Externí odkaz:
https://doaj.org/article/01f57eda79e14688ad637ad305a17120
Publikováno v:
Cell & Bioscience, Vol 10, Iss 1, Pp 1-10 (2020)
Abstract Background Colorectal cancer (CRC) is the fourth most deadly malignancy throughout the world. Extensive studies have shown that Krüppel-like factors (KLFs) play essential roles in cancer development. However, the function of KLF13 in CRC is
Externí odkaz:
https://doaj.org/article/ea12417fdd3e4bcd9ef01ed18ddfd808
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-15 (2019)
Abstract Background 5-Fluorouracil (5-FU) is a standard treatment for colorectal cancer, but most patients develop 5-FU resistance. Here, we conducted experiments to identify an effective approach to augment 5-FU-based treatment in colorectal cancer
Externí odkaz:
https://doaj.org/article/d1be37d1627343d5addd830907fffe99
Publikováno v:
Molecular Carcinogenesis. 61:1031-1042
Autor:
Shi-Yong Sun, Xia He, Taofeek K. Owonikoko, Shaomeng Wang, Guojing Zhang, Weilong Yao, Giovanna C. Cavalcante, Jiajia Gu, Dan Zong
Basal levels of BRD4 mRNA in NSCLC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd7e8eced6aecf855c12432eeb411e9
https://doi.org/10.1158/0008-5472.22423452
https://doi.org/10.1158/0008-5472.22423452
Autor:
Jiajia Gu, Guojing Zhang, Puyu Shi, Taofeek K. Owonikoko, Weilong Yao, Suresh S. Ramalingam, Shi-Yong Sun
Publikováno v:
Cancer. 126:3788-3799
Background The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. The curre
Autor:
Guojing Zhang, Xia He, Taofeek K. Owonikoko, Shaomeng Wang, Shi-Yong Sun, Giovanna C. Cavalcante, Jiajia Gu, Weilong Yao, Dan Zong
Publikováno v:
Cancer Research. 80:2380-2393
Lung cancer consists of approximately 80% non–small cell lung cancer (NSCLC) and 20% small cell lung cancer (SCLC) and remains the leading cause of cancer-related deaths worldwide despite advances in early diagnosis, targeted therapy, and immunothe
Publikováno v:
Bioscience, Biotechnology, and Biochemistry. 83:2057-2064
miR-29a-3p has been reported to function as a tumor suppressor in several cancers. However, the biological function role of miR-29a-3p in colorectal carcinoma (CRC) has not been well investigated. In this study, we found that miR-29a-3p was at lower
Publikováno v:
Cancer letters. 519
The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line